Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy

2008 ◽  
Vol 50 (3) ◽  
pp. 627-629 ◽  
Author(s):  
Amy L. Dunn ◽  
Thomas C. Abshire
Keyword(s):  
Immune Tolerance ◽  
Central Venous Access ◽  
Recombinant Tissue Plasminogen Activator ◽  
Venous Access ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Device Infection ◽  
Tissue Plasminogen ◽  
Venous Access Device

Risk factors determining central venous access device-associated deep vein thrombosis resolution in children: a retrospective study

2021 ◽  
Author(s):  
Miguel García-Boyano ◽  
José Manuel Caballero-Caballero ◽  
Marta García Fernández de Villalta ◽  
Mar Gutiérrez Alvariño ◽  
María Jesús Blanco Bañares ◽  
...  
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Vein Thrombosis ◽  
Venous Access Device ◽  
Deep Vein

scholarly journals How I treat central venous access device–related upper extremity deep vein thrombosis

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2727-2736 ◽  
Author(s):  
Anita Rajasekhar ◽  
Michael B. Streiff
Keyword(s):  
Central Venous Access ◽  
Vena Cava ◽  
Venous Access ◽  
Postthrombotic Syndrome ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Persistent Symptoms ◽  
Vena Cava Filters ◽  
Venous Access Device

AbstractCentral venous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring central venous access as part of their medical care. Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous access, and postthrombotic syndrome. Patient-, device-, and treatment-related factors can influence the risk of CRT. Despite numerous randomized controlled trials, the clinical benefit of pharmacologic thromboprophylaxis for the prevention of CRT remains to be established. Therefore, minimizing patient exposure to known risk factors is the best available approach to prevent CRT. Venous duplex is recommended for the diagnosis of CRT. Anticoagulation for at least 3 months or the duration of the indwelling CVAD is recommended for treatment of CRT. Thrombolysis should be considered for patients at low risk for bleeding who have limb-threatening thrombosis or whose symptoms fail to resolve with adequate anticoagulation. CVAD removal should be consider for patients with bacteremia, persistent symptoms despite anticoagulation, and if the CVAD is no longer needed. Superior vena cava filters should be avoided. Prospective studies are needed to define the optimal management of patients with or at risk for CRT.

Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland

Haemophilia ◽  
2015 ◽  
Vol 21 (6) ◽  
pp. 747-753 ◽  
Author(s):  
K. Vepsäläinen ◽  
R. Lassila ◽  
M. Arola ◽  
P. Lähteenmäki ◽  
M. Möttönen ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Central Venous Access ◽  
Venous Access ◽  
Haemophilia A ◽  
Central Venous ◽  
Central Venous Access Device ◽  
Access Device ◽  
Venous Access Device
Sign in / Sign up

Export Citation Format

Share Document